Leukemia Clinical Trials

Showing 3541-3560 of 10,987 trials

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

NCT05468242

The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced non-small cell lung cancer who have not progressed following neoadjuvant chemotherapy plus Tislelizumab ± Bevacizumab and definitive concurrent chemoradiation therapy.

Stage III Non-small Cell Lung Cancer

Sun Yat-sen University116 participantsStarted Jan 2022

Guangzhou, China

RECRUITING

Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML

NCT06665412

The goal of this observational study is to learn about the efficacy and safety profile when Radotinib dose redution is performed in Ph+ CML subjects. The main efficacy is checked by MMR rate by 12 months from IP treatment.

Chronic Phase Ph+ Chronic Myeloid Leukemia

Il-Yang Pharm. Co., Ltd.168 participantsStarted Oct 2024

Anyang-si, Gyeonnggi-do, South Korea • Daegu, South Korea

RECRUITINGPhase 2/3

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

NCT06288373

It is a prospective, open-label, randomized, controlled phase II/III clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB（tumors \>4 cm in diameter）will be enrolled and randomly divided into the neoadjuvant chemoimmunotherapy plus surgery group and the CCRT group.

Cervical CancerLocally Advanced Cervical CancerConcurrent Chemoradiotherapy+1 more

Tongji Hospital440 participantsStarted Apr 2024

Hefei, Anhui, China • Beijing, Beijing Municipality, China • Chongqing, Chongqing Municipality, China +9 more locations

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Related Searches

Effects of Home-Based Exercise Program in Children After Acute Lymphoblastic Leukemia

Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)

Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)

ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Effects of Hip Strengthening Training in Volleyball Players

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

Improvement of Quality of Life by Cannabinoids in Oncologic Patients

Opioid-Free Pain Treatment in Trauma Patients

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

CAR-T Cell Therapy Targeting to CD19 for R/R ALL

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia